

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA): Erratum

In ESH 2023 Guidelines [1], the color in columns 3, 4 and 5 of the row for Class of Recommendation I in Figure 2 has been corrected from white to dark blue in the online version of the paper to match the color used in all other Tables referring to the Level of Evidence. The color of the text has been changed from black to white to aid reading. The corrected Figure 2 is shown below. Additionally, in section 7.5 on page 1916, ‘... to minimize the problem of postexercise hypotension [411–413].’ should be changed to ‘... due to the immediate BP lowering effects of exercise [411–413].’

Class of Recommendation		Level of Evidence	
Definition		Definition	Interpretation
Evidence or general agreement that a treatment/test/procedure is beneficial, useful or effective AND that potential benefits clearly outweigh potential risk	A	- RCT or meta-analysis of RCTs with CVD outcomes - Single trial enough if sufficient power and without important limitations ^a	Strong evidence. Evidence of high certainty. Unlikely that future studies will change the effect estimate substantially
Conflicting evidence or opinion about the benefit, usefulness and effectiveness of a treatment/test/procedure OR uncertainty about benefit-risk balance	B	- RCT with surrogate measures (BP, HMOD) - Observational studies with CVD outcomes and no major limitations^a - Meta-analyses including the above study types	Moderate evidence. Evidence with some uncertainty. Future studies may modify, at least the magnitude of, the effect estimate
Evidence or general agreement that a treatment/test/procedure is not beneficial, useful or effective OR that potential risks outweigh the potential benefit	C	- Observational studies of surrogate measures - Any study type may be downgraded to level C due to limitations^a - Expert opinion (EO)	Weak evidence. Evidence of low certainty. Future studies may change the effect estimate substantially.

REFERENCE

1. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, *et al.* 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *J Hypertens* 2023; 41:1874–2071.